Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Coya Therapeutics, Inc. - Common Stock
(NQ:
COYA
)
6.220
UNCHANGED
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Coya Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
Next >
Coya Therapeutics Reports Additional Proof-of-Concept Clinical Biomarker Data in Patients with Alzheimer’s Disease
July 17, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
The Immunotherapy Market Is Expected To Surpass $351.56 Billion By 2030 – Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) Is Contributing to This Growth
July 12, 2023
Immunotherapy, in general, is an exciting and growing sector in the pharmaceutical industry. It involves manipulating the human body's immune system to treat various diseases. While historically this...
Via
Benzinga
Coya Therapeutics (“Coya”) Appoints Industry and Drug Development Veteran, Dr. Fred Grossman, to President and Chief Medical Officer succeeding Dr. Adrian Hepner
July 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
The Latest Analyst Ratings for Coya Therapeutics
June 08, 2023
Via
Benzinga
Coya Therapeutics: Another Sucess
May 16, 2023
The Coya story is just beginning and as the company expands with larger trials, the success in those trials will only increase the valuation of the company.
Via
Talk Markets
Why Coya Therapeutics Shares Are Shooting Higher Today
May 16, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported results from an open-label proof-of-concept clinical study for COYA 301 in
Via
Benzinga
Coya Therapeutics to Present Proof-of-Concept Clinical Data for Low-Dose Interleukin-2 (ld IL-2) for the Treatment of Patients with Alzheimer’s Disease (AD) at the 2023 Alzheimer’s Association International Conference (AAIC)
June 28, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. (Coya) Broadens its COYA 300 Biologics Patent Estate for the Exclusive Patent Rights and Know-how in treatment of Parkinson's Disease (PD)
June 20, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Strengthens its Management Team with the Appointment of Dr. Michelle Frazier as Senior Vice President of Regulatory Affairs
June 14, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics’ CEO Dr. Howard Berman’s Letter to Stockholders
June 12, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics Reports Additional Biomarker and Imaging Data Showing Decrease in Neuroinflammation with COYA 301 in Alzheimer’s Disease
June 08, 2023
Via
Get News
Marsh & McLennan To Rally Around 14%? Here Are 10 Other Analyst Forecasts For Thursday
June 08, 2023
Raymond James cut the price target for Brinker International, Inc. (NYSE: EAT) from $46 to $42.5. Raymond James analyst Brian Vaccaro maintained an Outperform rating. Brinker shares fell 6.3% to close...
Via
Benzinga
Blood Biomarker, Brain Imaging Data Shows Coya Therapeutics' Alzheimer's Candidate Lowers Neuroinflammation
June 07, 2023
Coya Therapeutics Inc (NASDAQ: COYA) reported additional biomarker and brain imaging results from an open-label proof-of-concept study for COYA 301 for
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
June 07, 2023
Via
Benzinga
Coya Therapeutics Reports Additional Blood Biomarker and Brain Imaging Data Showing Decrease in Neuroinflammation Following Treatment with COYA 301 in Alzheimer’s Disease (AD)
June 07, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket
June 06, 2023
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading.
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
June 06, 2023
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning!
Via
InvestorPlace
Coya Therapeutics Strengthens Scientific Advisory Board (SAB) with the Addition of Neuroimmunology Pioneer, Dr. Guillaume Dorothée, an Expert on the Role of the Immune System and Regulatory T Cells (Tregs) in Alzheimer’s Disease (AD)
June 05, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
12 Health Care Stocks Moving In Thursday's After-Market Session
June 01, 2023
Via
Benzinga
Coya to Present Additional Biomarker and Brain Imaging Data for COYA 301 in Alzheimer’s Disease (AD) at the LD Micro Conference on June 7, 2023
May 22, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
May 18, 2023
Via
Benzinga
Tesla, Manchester United, Ohmyhome, Target, Coya: Why These 5 Stocks Are Drawing Investor Attention Today
May 16, 2023
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
May 16, 2023
Via
Benzinga
Coya Therapeutics’ COYA 301 Increased Treg Function and Halted Cognitive Decline in an Open Label Study in Patients with Alzheimer’s Disease
May 16, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. Provides Business Update and Reports Q1 2023 Unaudited Financial Results
May 10, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Coya Therapeutics, Inc. to Present at the Sidoti Virtual Investor Conference on Thursday, May 11, 2023, at 2:30pm ET
May 09, 2023
From
Coya Therapeutics, Inc.
Via
Business Wire
Positive Financials Along With Promising Clinical Results – Coya Therapeutics
May 08, 2023
Howard Berman, Ph.D., CEO & Chairman of the Board of Coya Therapeutics, Inc. (NASDAQ: COYA), was recently a guest on Benzinga’s All Access.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
May 03, 2023
Via
Benzinga
Coya Therapeutics: An Attractive Valuation And First Set Of Data
April 19, 2023
Coya recent data in ALS seems under appreciated by the market and upcoming data in Alzheimer's offers the opportunity to confirm the early signals of efficacy in neurological conditions.
Via
Talk Markets
Alzheimer’s Disease Largely Remains A Mystery, With A Lack Of Highly Effective Treatments - Could Regulatory T-Cells (Tregs) Be The Answer?
April 14, 2023
Via
ACCESSWIRE
< Previous
1
2
3
4
5
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.